Scarica l'app Stockscreener
1.38
0.00%
0.00
Dopo l'orario di chiusura:
1.39
0.01
+0.72%
Precedente Chiudi:
$1.38
Aprire:
$1.36
Volume 24 ore:
87,733
Relative Volume:
0.83
Capitalizzazione di mercato:
$72.42M
Reddito:
-
Utile/perdita netta:
$-4.61M
Rapporto P/E:
-11.00
EPS:
-0.1254
Flusso di cassa netto:
$-3.10M
1 W Prestazione:
+1.47%
1M Prestazione:
-11.54%
6M Prestazione:
-12.66%
1 anno Prestazione:
-37.84%
Intervallo 1D:
$1.32
$1.40
Intervallo di 1 settimana:
$1.2862
$1.41
Portata 52W:
$1.28
$3.20
Okyo Pharma Limited Stock (OKYO) Company Profile
Nome
Okyo Pharma Limited
Settore
Industria
Telefono
-
Indirizzo
-
Compare OKYO vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.38 | 72.42M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Iniziato | Piper Sandler | Overweight |
| 2025-12-08 | Iniziato | B. Riley Securities | Buy |
Okyo Pharma Limited Borsa (OKYO) Ultime notizie
OKYO Pharma Ltd Share PriceOKYO, RNS News, Articles, Quotes, & Charts (NASDAQ:OKYO) - Proactive financial news
OKYO Pharma (NASDAQ: OKYO) to Host Fireside Chat at Cantor Global Healthcare Conference on September 10, 2026 - Kalkine Media
OKYO Pharma to Showcase Urcosimod at Key European Ophthalmology Forums - TipRanks
111-patient eye pain trial planned by OKYO Pharma (NASDAQ: OKYO) - Stock Titan
OKYO Pharma (OKYO) to Showcase Advances at Ophthalmology Futures Forum and ESCRS iNovation Day Amid Phase 3 NEPTUNE Trial Progress - Kalkine Media
A late-stage trial is planned to test a one-dose treatment for corneal nerve pain - Stock Titan
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 - manilatimes.net
OKYO Pharma Ltd ADR (NASDAQ: OKYO) Share Price, OKYO Stock News, OKYO Share Price & Updates - Kalkine
OKYO Pharma (NASDAQ: OKYO) readies Phase 3 trial of eye-pain drug urcosimod - Stock Titan
OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference - marketscreener.com
OKYO Pharma to participate in Cantor Global Healthcare Conference - Proactive financial news
Piper Sandler Maintains OKYO Pharma(OKYO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OKYO (OKYO) Trading: Ends Higher by 2.67% at $1.54 in the Latest Reading; Traders Can Monitor the $1.46-$1.62 Range under the Current SnapshotFactor ETF Flow - dars.gov.et
OKYO (OKYO) Session: Posts a 2.67% Gain to $1.54 in Latest Trading; Chart Watch: Price Remains Between $1.46 Support and $1.62 Resistance in the Latest ReadingVolatility Surface - vinanet.vn
OKYO (OKYO) Watch: Declines 0.33% to $1.51 on the Day; Key Range: the Supplied Trading Band Runs From $1.43 to $1.59 for the Current SessionCounter Trend Trade - vinanet.vn
OKYO Pharma (OKYO) Edges Up 1.33% to $1.52 as Support at $1.44 HoldsCalendar Spread Trade - vinanet.vn
Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4% - MarketBeat
OKYO Pharma Ltd (OKYO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKYO Pharma (NASDAQ: OKYO) updates 20-F to add clawback policy exhibit - stocktitan.net
OKYO Pharma (OKYO) director buys 5,000 shares in open market - Stock Titan
Price to sales forward of OKYO Pharma Limited – NASDAQ:OKYO - tradingview.com
OKYO Pharma (OKYO) Expected to Post Quarterly Earnings on Monday - MarketBeat
Form 4 OKYO Pharma Ltd For: 29 July By Investing.com - Investing.com Canada
OKYO Pharma CSO buys shares - Proactive financial news
OKYO Pharma CSO purchases additional shares at $1.49 By Investing.com - Investing.com Nigeria
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CSO boosts stake, plans Phase 3 NCP trial - Stock Titan
OKYO Pharma scientist's holdings reach 20,030 shares after purchase - Stock Titan
OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial - TipRanks
OKYO Pharma to participate in BTIG Biotechnology Conference 2026 - Proactive financial news
OKYO Pharma Ltd (OKYO) Cash Flow - TradingKey
OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans - simplywall.st
OKYO Pharma to Participate in BTIG Biotechnology Conference 2026 - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference - Stock Titan
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - GlobeNewswire
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Limited Revenue Breakdown – GETTEX:OK11 - TradingView
OKYO|OKYO Pharma Ltd|Price:1.530|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain - Ophthalmology Times Europe
Form 4 OKYO Pharma Ltd For: 24 July By Investing.com - Investing.com South Africa
OKYO Pharma Declines Slightly, Tests Support Near $1.39 as Biotech Sector Faces PressureSmall Cap Breakouts - careplusvn.com
OKYO Pharma (OKYO) grants 3,500 shares to chief development officer - Stock Titan
OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch - Kalkine Media
OKYO Pharma director buys 5,000 shares at $1.48, increasing his stake to 35,201 shares. - Pluang
OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq - Quiver Quantitative
Okyo Pharma Limited Azioni (OKYO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):